One more free stock for me: 3SBIO (SSRX) happily hit my +40% mark! November 23, 2009Posted by deminvest in 3SBIO Pharma, China stock, growth stock, investment, investment strategies, my free stock.
Tags: biotech, Pharma
add a comment
3SBio is a Chinese Biotech company.
I bought 110 SSRX shares on Aug 1 2008 for $9.15 each. I spent a total amount of $1001.5
Today I sold 77 SSRX shares @ $13.21. I made a total amount of $ 1017.17.
I am $11 richer and I do own 33 free SSRX shares, which hopefully one day will make me rich, thanks to my free stocks strategy.
Again I can’t resist bargains: (SSRX) 3SBIO Chinese biotech company had plenty of cash and nice growth August 1, 2008Posted by deminvest in 3SBIO Pharma, China stock, growth stock, investment, nasdaq, Nasdaq stock, SSRX, stock I own, stocks.
I studied it last week and buyed it today: this is my zecco order:
|08/01/2008 3:56 PM||SSRX||110||Buy at $9.15||
I did it beacuse this reserch biotech company already has ok P/E=15, is growing well and has a piplene and plenty of cash to develope new pharmaceuticals.
This move is a bit crazy. Last week I thought I’d buy CMED… but we will see.
Medical in China may be key to invest in August. Candidates are: China Medical Technologies (CMED), (MR) Mindray Medical, (SCR) Simcere Pharmaceutical, (SSRX) 3SBIO Pharma, (WX) WuXi Pharmatech July 23, 2008Posted by deminvest in 3SBIO Pharma, China Medical Technologies, China Mobile, China stock, CHL, CMED, growth stock, Mindray Medical, MR, nasdaq, Nasdaq stock, SCR, Simcere Pharmaceutical, Single stocks, SSRX, stocks.
Tags: China, Chinese, Chinese Economy, Far East, Healthcare, Medical, Pharmaceutical, US Economy
When I see US Economy stuck and China Economy growing 10% pace my simple mind thinks:
1) I want to invest in China rather than in the US
2) I don’t want to invest in a Chinese company which exports to US
So I wonder… what will Chinese people spend on, as soon as they have some money in their pockets. The answer is easy. First on Cell phone, second on (CHL) China Mobile, China’s largest Cell Phone company, I should look at the Medical business.. Since I already am an happy owner of
CMED is a (healthy)company. China Medical Technologies provides tools for medical analysis, specially connected with fertility problems. CMED is quite expensive with Trailing P/E: 26 and Forward P/E: 15. What is interesting is the fact that China Medical Technologies is growing its Revenues 74.30% year on year. Earnings had a slower growth of 17.50%, but that is probably because the company is now mainly focused in gaining market shares and growing. CMED also pays a 1.00% dividend yield which is nice for such growth company.
MR is a larger than CME. Mindray had a nice growth: 8% yoy revenue growth 46% earnings growth yoy are strong and interesting. The fact that Mindray owns $313.84M of cash, about 8% of its Market Cap, is also pretty good.
(SCR) Simcere Pharmaceutical mainly produces generic pharmaceuticals which are good specially in an overpopulated and still poor country like China. Current P/E around 15 is an honest price-tag for a company that grew with Qtrly Revenue Growth (yoy):26.40% and Qtrly Earnings Growth (yoy):67.50%. Also 130 Millions cash are great news for a company that is valued as a whole 770 Million Market Cap.
(SSRX) 3SBIO is a Chinese biotech company that does biotech research for new pharmaceuticals. At 3SBIO they have already developed two good one:s EPIAO and TPIAO for blood diseases. Those two already guarantee Trailing P/E (yoy):16 and Forward P/E:12 which are excellent for a company that still plenty of cash for new research: SSRX owns 115.71M cash, more than half the market CAP 197.72M.
Market Cap: 195.99M. Meaning that half of this company’s price is made by cash.
(WX) WuXi Pharmatech is a Chinese – American company that offers services and products to Biotech research companies. I don’t like it because, from what I understood, it doesn’t do its own research, but gets pay by other biotech companies to help them. This should mean WX will never hit a Bingo. Also it is quite expensive, compared to the above: Trailing P/E :32.24, Forward P/E: 18.68. I must admit growth rates are impressing: Qtrly Revenue Growth (yoy):68.70%, Qtrly Earnings Growth :131.90%.